Akari Therapeutics, Plc Cash and Restricted Cash
Akari Therapeutics, Plc (AKTX) had Cash and Restricted Cash of $7.75 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.75M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.83M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.26M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.54M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $7.75M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.83M 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $5.26M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $2.54M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $2.77M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $2.64M 10-Q · filed 2026-05-19 | |
| 2024-12-31 | $2.66M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $2.25M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $4.18M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $1.31M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $3.85M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $4.73M 10-Q · filed 2024-11-19 | |
| 2023-06-30 | $274.37K 8-K · filed 2024-09-06 | $7.18M 6-K · filed 2023-09-29 |
| 2023-03-31 | $11.58M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $13.25M 10-K · filed 2025-04-15 | $13.25M 20-F · filed 2023-05-01 |
| 2022-06-30 | $8.15M 6-K · filed 2023-09-29 | |
| 2021-12-31 | $442.48K 8-K · filed 2024-09-06 | $9.36M 20-F · filed 2022-05-16 |
| 2021-06-30 | $3.79M 6-K · filed 2022-09-27 | |
| 2020-12-31 | $14.06M 20-F · filed 2023-05-01 | |
| 2020-09-30 | $12.32M 20-F · filed 2021-04-21 | |
| 2020-06-30 | $12.75M 6-K · filed 2021-09-22 | |
| 2020-03-31 | $7.82M 20-F · filed 2021-04-21 | |
| 2019-12-31 | $5.73M 20-F · filed 2023-05-01 | |
| 2019-09-30 | $6.27M 20-F · filed 2021-04-21 | |
| 2019-06-30 | $2.75M 20-F · filed 2021-04-21 | |
| 2019-03-31 | $6.29M 20-F · filed 2021-04-21 | |
| 2018-12-31 | $5.97M 20-F · filed 2022-05-16 | |
| 2018-06-30 | $15.59M 6-K · filed 2019-08-29 | |
| 2017-12-31 | $28.25M 20-F · filed 2021-04-21 | |
| 2016-12-31 | $34.24M 20-F · filed 2020-03-31 | |
| 2015-12-31 | $69.06M 20-F · filed 2019-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |